Study title:
A phase I feasibility trial of a live, genetically modified Salmonella typhimurium bacillus (VNP20009) for the treatment of cancer by intra-tumoral injection
Date receipt dossier:
25 jun 1999
Pharmaceutical study code:
CLI-007
Company / Sponsor:
Vion Pharmaceuticals, Inc.
Phase:
I
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
Non-hematologic malignancies
Therapeutic approach:
Tumor colonization
Genetic modification:
Not relevant
Method of transfer of nucleic acid of interest:
Not relevant
Administered biological material:
Genetically modified Salmonella typhimurium bacillus
Route of administration:
Intratumoral
Locations in Belgium:
Universitair Ziekenhuis Gasthuisberg, Leuven
Type of procedure:
Contained use only
Notes:
Trial never started in Belgium